Vibergron is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of acute urinary incontinence, urgency, and frequency.

LuciVibe simple instructions

Please use under the guidance of a physician

Product Name: LuciVibe

Manufacturer: Lucius Pharmaceuticals (Laos) Co., Ltd.

Chinese name: Weibeglong tablets

English name: Vibegron tablets

Drug approval number: 07 L 1140/24

 

【Indications】

LuciVibe is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) in adults with symptoms of acute urinary incontinence, urgency, and frequency.

 

【Usage and Dosage】

•The recommended dose is 75 mg orally once daily.

•Swallow the tablet whole with water.

•Tablets may be crushed and taken with food.

 

【Specification】

75mg/tablet, 30 tablets/box.

 

【Contraindications】

Do not use if you have an allergic reaction to Vibergron or other ingredients in the product.

 

【 Warnings and precautions 】

Urinary Retention: Monitor for urinary retention, particularly in patients with bladder outlet obstruction and those taking muscarinic antagonists for OAB, who may be at greater risk for urinary retention. If urinary retention occurs, discontinue use of LuciVibe.

 

【Adverse Reactions】

The most common adverse reactions (≥2%) reported with LuciVibe were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

【Drug Interactions】

Digoxin: Measure serum digoxin concentrations before starting LuciVibe.

Monitor serum digoxin concentrations to titrate digoxin doses to achieve the desired clinical effect.

 

【Use by specific groups】

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

End-stage renal disease with or without hemodialysis: Not recommended.

Patients with severe liver impairment: Not recommended.

【Storage】

Storage temperature is 20℃ to 25℃ (68℉ to 77℉), short-distance transportation is allowed between 15℃ to 30℃ (59℉ to 86℉). Protect from moisture.